Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
113.27
+0.51 (+0.45%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Abbott Laboratories
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
How Did Healthcare Stocks Perform Over This Volatile Month?
December 06, 2021
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%.
Via
Talk Markets
Watch for Continued Gains in Shares of Abbott Laboratories
December 06, 2021
Shares of Abbott Laboratories (NYSE: ABT) traded today at $132.41, eclipsing its 12-month high. Approximately 1.4 million shares have changed hands today, as compared to an...
Via
Benzinga
7 Stocks to Buy to Give Your Portfolio a Booster Shot
December 06, 2021
With the new strain already reported in the U.S., it’s time to consider some adjustments to your portfolio.
Via
InvestorPlace
Exposures
COVID-19
Abbott Labs Stock Climbs Into Top-Performers Group Amid Continued double- and triple-digit Profit, Sales Growth
December 06, 2021
A Relative Strength Rating upgrade for Abbott Laboratories shows improving technical performance.
Via
Investor's Business Daily
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
December 03, 2021
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech.
Via
InvestorPlace
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
December 03, 2021
President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened...
Via
Benzinga
Exposures
COVID-19
Notable Abbott Laboratories Insider Trades $5.5M In Company Stock
November 18, 2021
Gregory A Ahlberg, Insider at Abbott Laboratories (NYSE:ABT), made a large buy and sell of company shares on November 15, according to a new SEC filing. What Happened: A Form 4...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Danaher Stock Shows Renewed Strength, Earning Key Rating Hike Amid Rising Profits, Sales
November 18, 2021
A Relative Strength Rating upgrade for Danaher shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Better Buy: DexCom or Abbott Labs?
November 17, 2021
Abbott's the heavyweight, and DexCom is the formidable challenger.
Via
The Motley Fool
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...
Via
Benzinga
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
November 12, 2021
Johnson & Johnson will split its consumer health unit into a publicly traded company.
Via
Investor's Business Daily
2 Dividend Aristocrats That Could Announce Generous Rate Hikes in December
November 11, 2021
Buy now to take advantage of what will likely be higher yields to come.
Via
The Motley Fool
10 S&P 500 Stocks to Buy After Winning in Q3
November 05, 2021
Earnings reports for S&P 500 stocks have been exceptionally good so far. Here are 10 stocks to buy that have delivered in Q3.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Lilly Stock Receives Key IBD Stock Rating Upgrade; Looking To Extend Its Long Run Higher
November 04, 2021
Lilly stock's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
Via
Investor's Business Daily
7 Dividend Aristocrat Stocks That Should Grace Your Portfolio
November 03, 2021
You get a lot more more from dividend aristocrat stocks than just a rock-solid dividend. They also promise solid, long-term growth.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Vice President Of Abbott Laboratories Makes $1.0M Sale
October 28, 2021
Philip P Boudreau, Vice President at Abbott Laboratories (NYSE:ABT), made a large insider sell on October 25, according to a new SEC filing. What Happened: A Form 4 filing from...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Edwards Topples As Full-Year Guidance Comes In Light After Mixed Quarter
October 27, 2021
The company retained guidance for adjusted profit of $2.07-$2.27, missing the midpoint of analysts' view.
Via
Investor's Business Daily
Where Abbott Laboratories Stands With Analysts
October 27, 2021
Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021
October 27, 2021
Upgrades According to Credit Suisse, the prior rating for Mercer International Inc (NASDAQ:
Via
Benzinga
Got $5,000? These 2 Unstoppable Stocks Are No-Brainer Buys
October 26, 2021
Both are great places to park your money for years.
Via
The Motley Fool
Kimberly-Clark's Earnings Remind Investors that Inflation and Supply Chain Issues are Still a Major Theme
October 25, 2021
This week is a big one for earnings, not just because of the big names reporting but because of the large number of earnings announcements. Investors can expect the themes of...
Via
Benzinga
Will Tech Stocks Derail the 3Q21 Earnings Rally?
October 24, 2021
S&P 500 equities continued to post robust 3rd quarter earnings reports, staying on track to grow EPS by 32.7% year-over-year. Over 84% of those reporting topped analysts’ forecasts. The damage from a...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
AbbVie: A Healthy Idea For Retirement Portfolios
October 23, 2021
The healthcare industry is among the cheapest sectors in today's market, and this pandemic has validated its importance for the economy and our overall well-being. Over the next decade, we will see...
Via
Talk Markets
Topics
Economy
Retirement
Exposures
Economy
Pension
A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
October 22, 2021
Key takeaways Four rounds of fundraising together with IPO proceeds have given the Abbisko a cumulative war chest of almost $500 million Company is betting a significant portion...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Where Abbott Laboratories Stands With Analysts
October 21, 2021
Over the past 3 months, 4 analysts have published their opinion on Abbott Laboratories (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Thursday
October 21, 2021
Wedbush boosted Tesla, Inc. (NASDAQ:TSLA) price ...
Via
Benzinga
3 Things Investors Should Love About Abbott's Q3 Results
October 21, 2021
There was nothing but good news for Abbott in Q3.
Via
The Motley Fool
Why Abbott Laboratories Shot Higher Today
October 20, 2021
All four of the company's divisions posted strong growth, but one in particular was a standout.
Via
The Motley Fool
Abbott Laboratories (ABT) Q3 2021 Earnings Call Transcript
October 20, 2021
ABT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
October 20, 2021
Just before Tuesday’s close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company...
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.